Hosp. Del Mar

Barcelona 8003

2 studies enrolling now · 21 studies all time

What they study most

Acute Coronary Syndrome, Alzheimer Disease, Arthritis, Psoriatic, Atrial Fibrillation, Bipolar Disorder, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-small-Cell Lung, Castration-Resistant Prostatic Cancer, Cognitive Dysfunction, Colorectal Neoplasms, Crohn Disease, Dementia

Studies at this site

• A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy — Recruiting now
• A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer — Recruiting now
• A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE — Running, not enrolling
• A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer — Running, not enrolling
• A Study of Daratumumab — Running, not enrolling
• A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer — Running, not enrolling
• A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation — Running, not enrolling
• Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension — Running, not enrolling
• A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome — Completed
• A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years — Completed
• A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet) — Running, not enrolling
• A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health — Completed
• A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy — Completed
• A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease — Stopped early
• A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer — Running, not enrolling
• A Study of JNJ-55308942 in the Treatment of Bipolar Depression — Completed
• A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy — Completed
• Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year — Completed
• Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection — Stopped early
• A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s) — Completed
• A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis — Completed